BizNewsConnect

Omicron? Russia says Sputnik V is effective

Jab induces robust neutralizing antibody response

RDIF says Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster are effective against Omicron variant of COVID

NEW DELHI, Dec 17 (The CONNECT) - A preliminary laboratory study conducted by the Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster are effective against Omicron (B.1.1.529) variant of COVID, providing for better protection when compared to other vaccines, an official Russian agency said.

Heterologous boosting with Sputnik Light is the solution to increase other vaccines’ efficacy, including against Omicron, and extend the booster protection period, Russian Direct Investment Fund that is supporting Sputnik V development said.

Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response.

Efficacy of mRNA vaccines has proven to be waning, demonstrated by a number of scientific publications. A Swedish study in The Lancet journal[1] has shown that Pfizer vaccine’s efficacy against Delta is falling to 47% after 4 months, to 29% after 6 months and to 23% after 7 months. The recent study in US among 65+ years olds demonstrated the decrease in mRNA vaccine effectiveness accelerating against Delta after month 4, reaching a low of approximately 20% in months 5 through 7[2].

Recognizing the waning efficacy of mRNA vaccines, EU, UK, Greece, South Korea and other countries have recommended reducing the boosting period from 6 to 3 months.

Sputnik Light booster is recommended to strengthen efficacy of vaccines against Omicron. Boosting by Sputnik Light as well as heterologous boosting can strengthen and lengthen the quickly waning efficacy of many vaccines in light of combined Delta and Omicron challenge.

Sputnik Light has already been registered in more than 20 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, UAE, Bahrain, Philippines, and San Marino). Sputnik V has been authorized in 71 countries with total population of over 4 billion people.

Sputnik Light has already shown strong results used as a booster in mix & match trials in Argentina. A combination of Sputnik Light with vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino, conducted in 5 provinces (City and Province of Buenos Aires, as well as Córdoba, La Rioja and San Luis) has demonstrated that Sputnik Light induces stronger antibody and T-cell response as compared to homologous regimen (two shots of the same vaccine). Each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on the 14th day after administering a second dose when compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.

Authors of a study in Argentina have noted that protection against coronavirus remains stable over at least 4 months following vaccination with the Russian Sputnik V vaccine as a consequence of antibody maturation, resulting in improved potency of antibodies to viral escape mutations. The study results were summarized in this article.

Recent News

Advertisement